TMDXTransMedics Group, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.
Priced for ~13% a year FCF growth. The price demands less than its three-year revenue growth of 64% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TMDX's price assumes
TransMedics Group, Inc. trades at 20.2× earnings against 26.2× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 26.2 · cheaper than the typical name in its group
- Price / sales
- 4.02
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 2.9%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; revenue has grown +64% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.19
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 27.1
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.32
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Free cash flow, trailing twelve months
- $79M
- Market capitalisation
- $2.69B
- 3-year revenue growth
- +64%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.